Staar Surgical (NASDAQ: STAA) is a medical device company that designs, develops, and manufactures implantable lenses for the eye. Its main products offer an alternative to glasses, contact lenses, or LASIK surgery for vision correction. The company operates in a competitive market, facing rivals that offer other vision correction technologies.
An analyst from Piper Sandler, Adam Maeder, recently increased the price target for Staar Surgical to $33.00, a significant jump from the previous target of $16.00. This new target was established while the stock was trading at $29.40, indicating the analyst sees potential for the stock's price to continue rising.
This positive outlook is supported by the company's strong financial rebound. As highlighted by MarketBeat, Staar Surgical reported first-quarter net sales of $93.50 million, a 119.6% increase from the prior year. This growth is driven by strong demand in China and continued expansion in the United States.
The company also shows a major improvement in profitability. As noted by Zacks Investment Research, earnings per share (EPS) came in at $0.38. EPS shows how much profit is made per share of stock. This figure is a large improvement from a loss of $0.52 in the same quarter last year.
Company management states that many challenges from the previous year are now resolved. These issues included a potential merger with Alcon and high inventory levels in China. This suggests a more stable operating environment for Staar Surgical moving forward, supporting its recent performance.
